89 results about "Adhesion protein" patented technology

The invention belongs to the technical field of prevention and treatment of animal borne diseases, and relates to a mycoplasma bovis gene mutation strain having reduced adhesion capacity and adhesionprotein. The protein gene Mbov_0503 is cloned from a mycoplasma bovis HB0801 genome. According to the partiality properties of escherichia coli to codons, the Mbov_0503 gene is modified, and mycoplasma bovis tryptophan codons UGA are mutated into codons UGG for coding tryptophan in the escherichia coli, so that recombination protein Mbov0503 is obtained. The nucleotide sequence of the protein geneis shown as SEQID NO:13, and the coded protein sequence is shown as SEQID NO:14. The mutation strain is the adhesion defect strain screened from a mutant library. Compared with wild strains, the mutation stain has the advantages that the adhesion capacity to host EBL cells, the cross-membrane transmission capacity to MDBK cells and destructivity to tight connection between cells of the mutation strain are notably reduced. The mycoplasma bovis gene mutation strain can be used for prevention and treatment of mycoplasma bovis diseases.

The fish and shrimp phagostimulant of fermented product and adsorbed protein is prepared through screening beneficial bacteria seed from cultivated animal body, culturing in composite culture medium to proliferate, concentrating and adding plant protein with phagostimulant effect. It is added into fish and shrimp feed to raise their feed intake and improve their digesting function. The production process has combined beneficial microbe fermenting technology and low temperature drying technology to ensure the fast growth of beneficial bacteria, the well preservation of metabolic product and the special cultivating function. The fish and shrimp phagostimulant is one kind of green product capable of replacing traditional phagostimulant and antioxidant.

The invention discloses a preparation method of a fusion protein (SEQ ID No: 4) of a decamer containing a metal binding polypeptide and a connecting peptide, and a skin cell adhesion tripeptide, and an application of the fusion protein, especially an application of the fusion protein in the field of cosmetics. The preparation method disclosed by the invention is characterized by comprising the following steps of: obtaining a DNA sequence (SEQ ID No: 8) for coding the fusion protein of the decamer containing the metal binding polypeptide and the connecting peptide, and the skin cell adhesion tripeptide by virtue of a gene engineering technique, and then performing recombination expression by a surface display method in lactic acid bacteria. As the metal binding polypeptide and the skin cell adhesion protein have the abilities of binding harmful heavy metal ions and increasing the adhesive skin of an expression host, respectively, the cosmetics prepared from lactic acid engineering bacteria of the fusion protein of the decamer containing the metal binding polypeptide and the connecting peptide and the skin cell adhesion tripeptide expressed by the surface display method are capable of effectively reducing accumulation of toxic heavy metals in skin; and therefore, the effect of bioremediation is achieved.

Systems for assaying human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) are provided. Aspects of the systems include a traction force microscopy substrate, such as a traction force microscopy hydrogel (TFM-hydrogel), having an adhesion protein domain on a surface thereof; a video imager configured to obtain video data from an hiPSC-CM present on the adhesion protein domain; and a processing module configured to receive the video data and derive a parameter of the hiPSC-CM therefrom. Also provided are methods of using the systems.

The invention relates to a highly bioactive extracellular matrix material and a preparation method and an application thereof. The material is prepared from raw materials with combined use of ultra-high pressure and cavity internal and external perfusion. The preparation method mainly includes the steps: raw material obtaining and preparation, and pretreatment; extracellular matrix mechanical separation; ultra-high pressure crushing and decellularizing; cell content elution and antigen elimination; and ultimately disinfection, sterilization and preservation. Compared with an extracellular matrix obtained by decellularizing through a mechanical oscillation method and a chemical reagent or biological reagent method, the extracellular matrix obtained by the preparation method has the retention amount of adhesion proteins, growth factors, proteoglycans, glycoproteins, glycosaminoglycans and other bioactive components significantly improved; at the same time, the mechanical strength is wellretained, the decellularizing is thorough, and viruses and other biological supporters are removed cleanly and industrialized production is convenient.

The present invention is directed to carbocyclic hydrazino compounds that function as inhibitors of copper-containing amine oxidases commonly known as semicarbazide-sensitive amine oxidases (SSAO), including the human SSAO known as Vascular Adhesion Protein-I (VAP-1). These SSAO inhibitors have therapeutic utility as drugs to treat conditions and diseases including, but not limited to, a number of inflammatory conditions and diseases (in particular chronic inflammatory conditions such as chronic arthritis, inflammatory bowel diseases, and chronic skin dermatoses), diseases related to carbohydrate metabolism and to aberrations in adipocyte differentiation or function and smooth muscle cell function, and vascular diseases. The novel compounds have the general formula:

or a pharmaceutically acceptable solvate, hydrate, or salt thereof wherein R¹ to R¹¹ are as defined herein.

The invention provides a method for screening and identifying adhesion proteins. The method is characterized by comprising the following steps of: carboxylating superficial magnetic beads; processing the carboxylated magnetic beads by using carbodiimide and sulfo-hydroxysuccinimide; covalently coupling the magnetic beads with enterocyte debris to form amido bonds; after cleaning the magnetic beads, incubating the magnetic beads and probiotic surface protein solution together for one hour; washing the magnetic beads by using PBS buffer solution for three times to remove non-adhesion surface proteins; eluting the adhesion proteins by using 50 mM of glycine hydrochloric acid buffer solution of which the pH value is 2.3; and after SDS-PAGE electrophoresis, sequencing by mass spectrometry to identify the adhesion proteins. The method for screening and identifying the adhesion proteins has the advantages that: a magnetic bead method makes use of the characteristic that the adhesion proteins can adhere enterocyte to combine the function and separation into one step, so that the efficiency of screening the adhesion proteins is greatly improved, and the adhesion proteins can be efficiently screened and identified in a high-throughput mode; and compared with the conventional chromatography method, the method has the advantages of low cost, time saving, labor saving, and capacity of screening and identifying a plurality of adhesion proteins in one step.

The invention belongs to the technical field of biology, relates to preparation of bionic nano-carriers and targeted treatment of arthritis, and particularly relates to a macrophage vesicle entrappednano-drug preparation and application thereof in treating arthritis. The nano-drug preparation targets an arthritis part through adhesive protein on the surface of a macrophage vesicle, and an immunosuppressive drug is delivered for targeted treatment of arthritis. Furthermore, a new strategy for targeted treatment of arthritis is provided for clinical practice, and the strategy comprises the steps of fusing an artificial drug carrier and the natural macrophage vesicle, and constructing the stable macrophage vesicle entrapped nano-drug preparation, thereby improving the targeted treatment effect of arthritis.

The invention belongs to the field of biomedical materials, and particularly relates to a preparation method of a cartilage acellular matrix composite scaffold and an application thereof. The structure of the cartilage acellular matrix composite scaffold is shown as a formula I, and the cartilage acellular matrix composite scaffold is a natural polymer or a derivative thereof and is a digested cartilage acellular matrix; wherein the mass percentage of the natural polymer or the derivative thereof is 25-75%, preferably 25-50%; wherein the mass percentage of the digested cartilage acellular matrix is 25-75%, preferably 50-75%. The invention discloses an acellular matrix/natural polymer composite material, after being implanted into a body, natural macromolecules or derivatives thereof are gradually degraded and absorbed in vivo, adhesion protein, growth factors and the like in acellular matrixes promote mesenchymal stem cells in bone marrow blood to differentiate into cartilage cells andmaintain the phenotype of the cartilage cells, the cartilage healing effect is effectively improved, a good operation curative effect is achieved, and the clinical application prospect is good.

The present invention provides highly porous, biocompatible and biostable scaffold constructs for improving overall cell engraftment, survival, function and long-term viability. These scaffolds can provide mechanical protection to implanted cells, afford retrievability from a subject, and allow for both intra-device vascularization and a means to spatially distribute the cells within the device. The scaffold surface or material may be modified with one or more different adhesion proteins and optionally other biological factors for enhanced cell adherence and viability. Further, the scaffold surface or material may be modified with one or more agents with slow/sustained release characteristics to aid engraftment, survival, function or long-term viability. Implanted cells of the invention may be insulin-producing cells such as islets.

The invention discloses 432 novel acetylation sites identified in signal transduction proteins and pathways underlying human protein acetylation signaling pathways, and provides acetylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these acetylated sites/proteins, as well as methods of using the reagents for such purpose. Among the acetylation sites identified are sites occurring in the following protein types: Acetyltransferases, Adaptor/Scaffold proteins, Actin binding proteins, Adhesion proteins, Apoptosis proteins, Calcium-binding proteins, Cell Cycle Regulation proteins, Cell Surface proteins, DNA binding proteins, DNA replication proteins, Channel proteins, Chaperone proteins, Cellular Metabolism enzymes, Cytoskeletal proteins, DNA repair proteins, Endoplasmic reticulum proteins, Enzyme proteins, G protein and GTPase Activating proteins, Guanine Nucleotide Exchange Factors, Helicase proteins, Isomerase proteins, Extracelluar matrix proteins, Hydrolases, Ligase proteins, Lipid kinases, Inhibtor proteins, Lipid Binding proteins and Lyases.

The invention provides application of Src kinase inhibitor in preparing medicaments for treating acute kidney injury. Further, the acute kidney injury is caused by renal ischemia. Further, the Src kinase inhibitor is PP1 (4-Amino-5-(methylphenyl)-7-(t-butyl)pyrazolo-(3,4-d)pyrimidine). The invention proves that PP1 inhibition of Src can relieve the pathobiological change of kidney after I/R, so as to improve kidney function. The treatment mechanism of the Src kinase inhibitor includes procedures of inhibiting apoptosis of renal tubule cells, protecting multiple connexins and adhesive proteins, and inhibiting cell death and inflammation signal pathway.

The invention discloses high adhesion clostridium butyricum and its preparation method, and belongs to the field of gene recombination. The invention provides the high adhesion clostridium butyricum and its preparation method to solve the technical problem, the main points of the technical proposal are that lactobacillus adhesion protein gene is obtained by cloning, and a lactobacillus adhesion protein gene-containing recombinant plasmid is converted into clostridium butyricum by use of a gene recombination method to obtain a clostridium butyricum recombinant strain. Through gene expression, the clostridium butyricum is capable of autologous production of a protein with the adhesion function, the adhesion ability is greatly improved, and the efficacy of the treatment of the clostridium butyricum is further improved.

The invention discloses nearly 443 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human carcinoma, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: Protein kinases (including Serine/Threonine dual specificity, and Tyrosine kinases), Adaptor/Scaffold proteins, Transcription factors, Phospoatases, Tumor supressors, Ubiquitin conjugating system proteins, Translation initiation complex proteins, RNA binding proteins, Apoptosis proteins, Adhesion proteins, G protein regulators/GTPase activating protein/Guanine nucleotide exchange factor proteins, and DNA binding/replication/repair proteins, as well as other protein types.

The invention belongs to the technical field of cosmetics, and specifically relates to a polypeptide composition and application thereof. The polypeptide composition comprises palmitoyl tripeptide-1,palmitoyl tripeptide-5, an epidermal growth factor, and tripeptide-1 copper. The polypeptide composition can be used for preparing cosmetics. The invention further provides a polypeptide-composition repair mask which mainly comprises the following components of the polypeptide composition, an anti-stimulating factor, a pH regulator, an absorption enhancer, a moisturizer, a thickener, a preservative and water. The absorption enhancer adopted by the mask can make the polypeptide composition more stable. The polypeptide-composition repair mask has the advantages of thickening epidermis, stimulating skin to produce collagen, elastin and adhesion protein, promoting skin cell metabolism, promoting repair and regeneration of damaged epidermis, and eliminating wrinkles and acne print on face, promoting wound healing and lightening scars.

The invention discloses an adhesion protein Apd and application thereof in preparation of a haemophilus parasuis indirect ELISA antibody detection kit. The invention verifies that the adhesion proteinApd is located on an outer membrane of the haemophilus parasuis, is expressed in 15 known serotypes respectively but does not exist in other bacterial pathogens of a pig, so that the adhesion proteinApd has high sensitivity and specificity when being taken as a diagnostic antigen. By optimizing expression and purification methods of a recombinant adhesion protein, a recombinant protein with goodimmunogenicity and reactionogenicity is obtained. By optimizing components and dosages as well as reaction conditions and result determination criterions of an indirect ELISA method taking the recombinant adhesion protein as an envelope antigen, the haemophilus parasuis indirect ELISA antibody detection kit is prepared. Animal experiments verify that the kit can be used for antibody detection after vaccine immunity and bacterial infection of the haemophilus parasuis. In comprehensive control and seroepidemiological investigation of a haemophilus parasuis disease, the kit can have a broad application prospect.